Marrone Bio Appoints Kevin Helash as Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
Marrone Bio Innovations (MBII) Names Kevin Helash as CEO
July 6, 2020 4:09 PM EDTMarrone Bio Innovations, Inc., (NASDAQ: MBII) today announced the appointment of Kevin Helash as its new chief executive officer. Concurrent with joining the company, he will be appointed to serve as a member of the board of directors. Helash, 55, a native of Manitoba, Canada, will join the company as early as August 1, 2020. His effective date is pending receipt of permanent residency status or the applicable visa, both of which are in process.
A 28-plus-year agricultural industry veteran, Helash comes to Marrone Bio from Agrinos AS, a global-scale biological crop input provider specializing in... More



